On Monday, Zydus Lifesciences said that it had received final approval from US health regulators to market its antacid famotidine tablets in the US market.

The company said in a statement that it had received approval from the USFDA to market the drug in 20 mg and 40 mg strengths.

Famotidine is a histamine H2 blocker that works by reducing the amount of acid in the stomach. It is used to prevent and treat heartburn and other symptoms caused by excess stomach acid.

Zydus Lifesciences said the drug would be manufactured at the group’s pharmaceutical formulation factory in the Ahmedabad Special Economic Zone. According to IQVIA MAT data in April 2022, the market size of famotidine tablets in the US is $67 million.